Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Surveys and Questionnaires 286Blood Specimen Collection 145Gene Expression Profiling 96Interviews as Topic 83Immunohistochemistry 78Polymerase Chain Reaction 64Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 58Microarray Analysis 55Flow Cytometry 53Radiotherapy 49Amplified Fragment Length Polymorphism Analysis 48Drug Therapy 46Observation 45Biopsy 42Reverse Transcriptase Polymerase Chain Reaction 39Bevacizumab 39Data Collection 35Sorafenib 29Psychiatric Rehabilitation 29Nivolumab 28palbociclib 26In Situ Hybridization, Fluorescence 26Rituximab 25Therapeutics 24Neoadjuvant Therapy 24Hepatectomy 24Docetaxel 24Colonoscopy 24Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Observational × Glycopeptides × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡